Atorvastatin: Difference between revisions
No edit summary |
References |
||
| Line 54: | Line 54: | ||
Because cholesterol synthesis decreases, hepatic cells increase the number of LDL receptors on the surface of the cells, which increase the amount of LDL uptake by the hepatic cells, and decreases the amount of LDL in the blood. |
Because cholesterol synthesis decreases, hepatic cells increase the number of LDL receptors on the surface of the cells, which increase the amount of LDL uptake by the hepatic cells, and decreases the amount of LDL in the blood. |
||
==References== |
|||
*[http://www.lipitor.com/cwp/appmanager/lipitor/lipitorDesktop?_nfpb=true&_pageLabel=prescribingInformation Lipitor: Prescribing Information.] (2004) Pfizer Ireland Pharmaceuticals. |
|||
== External links == |
== External links == |
||
Revision as of 20:42, 27 October 2004
|
| |
| [R-(R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid IUPAC name | |
| CAS number 134523-00-5 |
ATC code C10AA05 |
| Chemical formula | (C33H34FN2O5)2Ca•3H2O |
| Molecular weight | 1209.42 |
| Bioavailability | ? |
| Metabolism | Liver |
| Elimination half life | 14 hours |
| Excretion | Bile |
| Pregnancy category | ? |
| Legal status | ? |
| Delivery | ? |
In medicine and pharmacology, atorvastatin (Lipitor® or atorvastatin calcium) is a member of the drug class of statins, used for lowering cholesterol and preventing cardiovascular disease.
Unlike simvastatin and pravastatin, atorvastatin is a completely synthetic compound.
It is being marketed by the pharmaceutical company Pfizer.
Available forms
Atorvastatin is avaliable as Lipitor in tablet form (10, 20, 40 or 80 mg) for oral administration. Tablets are white, elliptical, and film coated.
Mechansim of Action
Atorvastatin is a competative inhibitor of HMG-CoA reductase. This enzyme catalyzes the reduction of 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, which is the rate limiting step in hepatic cholesterol synthesis.
Because cholesterol synthesis decreases, hepatic cells increase the number of LDL receptors on the surface of the cells, which increase the amount of LDL uptake by the hepatic cells, and decreases the amount of LDL in the blood.
References
- Lipitor: Prescribing Information. (2004) Pfizer Ireland Pharmaceuticals.
External links
- Manufacturer's site (lipitor.com)
 | The WikiProject banner below should be moved to this article's talk page. If this is a demonstration of the template, please set the parameter |category=no to prevent this page being miscategorised. |
 | Pharmacology NA‑class | ||||||
| |||||||